<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541047</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000571528</org_study_id>
    <secondary_id>MRC-RADICALS-PR10</secondary_id>
    <secondary_id>ISRCTN40814031</secondary_id>
    <secondary_id>EUDRACT-2006-000205-34</secondary_id>
    <secondary_id>EU-20767</secondary_id>
    <secondary_id>PR13</secondary_id>
    <secondary_id>PR13</secondary_id>
    <nct_id>NCT00541047</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)</brief_title>
  <official_title>RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause
      the growth of prostate cancer cells. Androgen deprivation therapy, such as goserelin,
      leuprolide, or bicalutamide, may lessen the amount of androgens made by the body. Giving
      radiation therapy together with androgen deprivation therapy may kill more prostate cancer
      cells.

      PURPOSE: This randomized phase III trial is studying how well giving radiation therapy
      together with androgen deprivation therapy works in treating patients who have undergone
      surgery for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the timing of radiotherapy and the use of hormone therapy in conjunction with
           post-operative radiotherapy.

        -  Determine the impact of radiotherapy on general quality of life, sexual function,
           urinary function, and bowel function.

        -  Determine the impact of duration of hormone therapy on general quality of life and
           sexual function.

      OUTLINE: This is a multicenter study. Patients requiring immediate radiotherapy (RT) are
      assigned to arm I; patients do not require immediate RT are assigned to arm II. Patients for
      whom the need of immediate post-operative radiotherapy are uncertain undergo radiotherapy
      timing randomization within 3 months after surgery and are randomized to 1 of 2 radiotherapy
      arms.

        -  Arm I (immediate RT): Within 2 months after randomization, patients undergo radiotherapy
           to the prostate bed once a day, 5 days a week, for 4 (20 fractions total) or 6.5 weeks
           (33 fractions total). They may also undergo radiotherapy to the pelvic lymph nodes once
           a day, 5 days a week, for 4.5 weeks (23 fractions total) at the investigator's
           discretion.

        -  Arm II (early salvage RT in case of PSA failure): Within 2 months of confirmation of
           post-operative biochemical failure, patients undergo radiotherapy as in arm I.

      Patients undergoing immediate RT and patients who eventually need early salvage RT undergo
      hormone therapy duration randomization before the administration of post-operative
      radiotherapy. Patients are randomized to 1 of 3 hormone therapy arms.

        -  Arm III (no hormone therapy): Patients do not receive hormone therapy. They receive
           post-operative RT alone as described above in arm I or II.

        -  Arm IV (RT and short-term hormone therapy): Beginning approximately 2 months prior to
           the start of RT, patients receive hormone therapy for 6 months. Hormone therapy* may
           comprise of LHRH agonist (gonadotrophin-releasing hormone analogue [GnRHa] [e.g.,
           goserelin or leuprolide acetate]) or bicalutamide daily.

        -  Arm V (RT and long-term hormone therapy): Beginning approximately 2 months prior to the
           start of RT, patients receive hormone therapy for 24 months. Hormone therapy* may
           comprise of LHRH agonist (gonadotrophin-releasing hormone analogue [GnRHa] [e.g.,
           goserelin or leuprolide acetate]) or bicalutamide daily.

      NOTE: *For Canadian patients, hormonal therapy will consist of LHRH analog (leuprolide
      acetate) therapy only.

      Treatment continues in the absence of disease progression or unacceptable toxicity. Quality
      of life is assessed using self-administered questionnaires at baseline and 1, 5, and 10 years
      after randomization. Health economics information is also collected via patient-administered
      questionnaires (EQ-5D) at baseline and at 1, 5 and 10 years after randomization.

      After completion of study treatment, patients are followed for 7 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific survival (i.e., death due to prostate cancer)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from treatment failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-protocol hormone therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">4236</enrollment>
  <condition>Gastrointestinal Complications</condition>
  <condition>Prostate Cancer</condition>
  <condition>Sexual Dysfunction</condition>
  <condition>Urinary Complications</condition>
  <arm_group>
    <arm_group_label>RADICALS-RT: Early RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RADICALS-RT: Salvage RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RADICALS-HD: Radiotherapy Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>RADICALS-RT: Early RT</arm_group_label>
    <arm_group_label>RADICALS-RT: Salvage RT</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy Alone</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>RADICALS-RT: Early RT</arm_group_label>
    <arm_group_label>RADICALS-RT: Salvage RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>RADICALS-RT: Early RT</arm_group_label>
    <arm_group_label>RADICALS-RT: Salvage RT</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy Alone</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 6 months</arm_group_label>
    <arm_group_label>RADICALS-HD: Radiotherapy + 24 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Diagnosis of nonmetastatic adenocarcinoma of the prostate

          -  Must have undergone radical prostatectomy

          -  Post-operative serum prostate-specific antigen (PSA) &lt; 0.4 ng/mL

          -  No post-operative biochemical failure, defined as EITHER two consecutive rises in PSA
             and final PSA &gt; 0.1 ng/mL OR three consecutive rises in PSA (for patients undergoing
             hormone therapy duration randomization)

        Exclusion criteria:

          -  Known distant metastases from prostate cancer

          -  PSA &gt; 5 ng/mL at the time of hormone randomization (for patients undergoing hormone
             therapy duration randomization)

        PATIENT CHARACTERISTICS:

          -  No other active malignancy likely to interfere with protocol treatment or follow-up

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

          -  Co-enrollment to other trials is permitted, providing this does not interfere with the
             outcome measures

          -  5-α reductase inhibitors, soya, selenium, and vitamin E are acceptable non-trial
             therapies

        Exclusion criteria:

          -  Prior hormone therapy

          -  Bilateral orchidectomy

          -  Prior pelvic radiotherapy

          -  Neoadjuvant treatment

          -  Other concurrent therapies for prostate cancer (e.g., estrogens or cytotoxic
             chemotherapy) prior to disease progression
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Parker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Harvey Hospital</name>
      <address>
        <city>Ashford-Kent</city>
        <state>England</state>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Devon District Hospital</name>
      <address>
        <city>Barnstaple</city>
        <state>England</state>
        <zip>EX31 4JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>England</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>England</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Cheshire Hospitals Trust- Leighton Hopsital</name>
      <address>
        <city>Crewe</city>
        <state>England</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayday University Hospital</name>
      <address>
        <city>Croydon</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <state>England</state>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital</name>
      <address>
        <city>Dorchester</city>
        <state>England</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Essex</city>
        <state>England</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <state>England</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>England</state>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen Rollason Cancer Care Centre at North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <state>England</state>
        <zip>RM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotherham General Hospital</name>
      <address>
        <city>Rotherham</city>
        <state>England</state>
        <zip>S60 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Salford</city>
        <state>England</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stepping Hill Hospital</name>
      <address>
        <city>Stockport</city>
        <state>England</state>
        <zip>SK2 7JE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire</name>
      <address>
        <city>Stoke-On-Trent</city>
        <state>England</state>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>England</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillingdon Hospital</name>
      <address>
        <city>Uxbridge</city>
        <state>England</state>
        <zip>UB8 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centre at York Hospital</name>
      <address>
        <city>York</city>
        <state>England</state>
        <zip>Y031 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinderfields General Hospital</name>
      <address>
        <city>Wakefield</city>
        <state>Scotland</state>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital</name>
      <address>
        <city>Newport Gwent</city>
        <state>Wales</state>
        <zip>NP9 2UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl, Denbighshire</city>
        <state>Wales</state>
        <zip>LL 18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Medical Research Council</investigator_full_name>
    <investigator_title>Mr</investigator_title>
  </responsible_party>
  <keyword>sexual dysfunction</keyword>
  <keyword>urinary complications</keyword>
  <keyword>gastrointestinal complications</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

